CNTG Centogene

CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners

CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 12, 2025 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”) today announced it has closed its transaction to sell its operating subsidiaries to an affiliate of Charme Capital Partners Limited (“Charme”).

As announced on November 13, 2024, the Company had entered into definitive agreements with Charme for the sale of 100% ownership in Centogene GmbH, CENTOGENE’s sole operating subsidiary, certain intercompany receivables, and assumption of the Company’s loan granted by Oxford Finance LLC (the “Transaction”).

On December 4, 2024, the Company held an Extraordinary General Meeting ("EGM") in connection with the Transaction, where shareholders voted in favor of all proposals.

Following the closing of the Transaction, the Company and its remaining subsidiary, Centogene Switzerland AG, will no longer have any operations. The Company intends to liquidate Centogene Switzerland AG, and the Company will enter dissolution and liquidation in accordance with the laws of the Netherlands and its organizational documents with effect from the consummation of the Transaction as resolved upon by its shareholders at the EGM.

It is currently expected that the Company will make a liquidation distribution to its shareholders. The exact liquidation distribution, if any, will take into account the Company’s anticipated running costs through the finalization of the liquidation and any reserves the Company may establish to satisfy expenses and other liabilities and to comply with applicable law. The exact record date and payment date of the liquidation distribution, if any, will be communicated by the Company on its investor website when available. The Company’s reporting obligations under the U.S. Securities Exchange Act have been suspended and the Company expects that its securities will cease to be quoted on the OTC market.

INVESTORS ARE ENCOURAGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE MATERIALS MADE AVAILABLE TO SHAREHOLDERS IN CONNECTION WITH THE EGM AND THE FORM 6-K FILED ON NOVEMBER 13, 2024, AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE TRANSACTION AND RELATED MATTERS.

This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in Centogene N.V. This announcement is not for release, publication, or distribution, in whole or in part, in or into, directly or indirectly, in any jurisdiction in which such release, publication or distribution would be unlawful.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is designed to,” “potential,” “predict,” “objective” and similar expressions and future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” and “may,” or the negative of these are generally intended to identify forward-looking statements. Forward-looking statements may include statements regarding the amount of funds (if any) from the Transaction available to pay to the Company’s stockholders in a liquidation distribution, the Company’s plans liquidate and dissolve, and any assumptions underlying any of the foregoing. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENE’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, (i) the amounts that will need to be set aside as reserves by the Company being higher than anticipated; (ii) potential unknown contingencies or liabilities and the Company’s ability to resolve them; (iii) the outcome of any legal proceedings related to the Transaction, the dissolution and liquidation of the Company or its subsidiaries or otherwise, (iv) economic, business and/or competitive factors that may adversely affect the Company, (v) negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, (vi) possible changes in current and proposed legislation, regulations and governmental policies, (vii) the Company’s ability to streamline cash usage and (viii) the Company’s continued ongoing compliance with covenants linked to financial instruments. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENE’s business in general, see CENTOGENE’s risk factors set forth in CENTOGENE’s Form 20-F filed on May 15, 2024, with the SEC and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT

Communications

Investor Relations

  



EN
12/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Centogene

 PRESS RELEASE

CENTOGENE Closes Strategic Transaction with Private Equity Group Charm...

CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 12, 2025 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”) today announced it has closed its transaction to sell its operating subsidiaries to an affiliate of Charme Capital Partners Limited (“Charme”). As announced on November 13, 2024, the Company had entered into definitive agreements with Charme for the sale of 100% ownership in Centogene GmbH, CENTOGENE’s sole operating subsidiary, certain intercompany receivabl...

 PRESS RELEASE

CENTOGENE Announces Voting Results of Extraordinary General Meeting

CENTOGENE Announces Voting Results of Extraordinary General Meeting Approval of All Resolutions, Including Announced Transaction With Charme Capital Partners CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Extraordinary General Meeting. Shareholders voted in favor of all proposals, which included the approval of the previously announced envisag...

 PRESS RELEASE

CENTOGENE Signs Strategic Transaction With Private Equity Group Charme...

CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its strategic review process and has entered into a Share Purchase Agreement (“SPA”) pursuant to which its operating subsidiaries will be sold to an affiliate of Charme Capital Partners Limited (“Charme”), a pan-European private eq...

 PRESS RELEASE

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in...

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findingsData from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Parkinson's patients than in the general population CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in ...

 PRESS RELEASE

CENTOGENE Receives Delisting Notice From Nasdaq

CENTOGENE Receives Delisting Notice From Nasdaq CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE’S common stock from Nasdaq. The notice indicates that CENTOGENE (the “Company”) remains noncompliant with Nasdaq Listing Rule 5450(b)(2)(C), which requires a minimum USD 15 million mark...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch